Eupraxia Pharmaceuticals Inc. (EPRX)
(Delayed Data from NSDQ)
$5.42 USD
+0.06 (1.14%)
Updated Aug 6, 2025 03:59 PM ET
After-Market: $5.39 -0.03 (-0.55%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Eupraxia Pharmaceuticals Inc.'s return on equity, or ROE, is -367.73% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that EPRX has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
EPRX 5.42 +0.06(1.14%)
Will EPRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for EPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for EPRX
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Analyst Coverage Initiated on EPRX with Overweight Rating | EPRX Stock News
Cantor Fitzgerald Assigns Overweight Rating to EPRX with $11 Price Target | EPRX Stock News
Eupraxia Pharmaceuticals initiated with bullish view at Cantor Fitzgerald
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences | EPRX Stock News